183 related articles for article (PubMed ID: 27501966)
21. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
Mehdi SA; Perry MC; Herndon JE; Crawford J; Young R; Graziano SL
J Interferon Cytokine Res; 1998 Aug; 18(8):623-7. PubMed ID: 9726444
[TBL] [Abstract][Full Text] [Related]
22. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
25. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy.
Zou L; Buchner A; Roberge M; Liu PM
J Immunol Res; 2016; 2016():9248061. PubMed ID: 27419145
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC; Szabo E; Gabriel S; Klastersky J; Tomey O; Mueller U; Schwartzberg L; Tang B
J Oncol Pharm Pract; 2018 Sep; 24(6):412-423. PubMed ID: 28614980
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
29. The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.
Holubec L; Polivka J; Lisnerova L; Kubikova T; Safanda M
In Vivo; 2017; 31(3):303-306. PubMed ID: 28438855
[TBL] [Abstract][Full Text] [Related]
30. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
[TBL] [Abstract][Full Text] [Related]
31. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
32. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
[TBL] [Abstract][Full Text] [Related]
33. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
34. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ
Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496
[TBL] [Abstract][Full Text] [Related]
35. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
[TBL] [Abstract][Full Text] [Related]
36. Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg.
Fontaine C; Claes N; Graas MP; Samani KK; Vuylsteke P; Vulsteke C
Acta Clin Belg; 2021 Feb; 76(1):10-15. PubMed ID: 31399016
[No Abstract] [Full Text] [Related]
37. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
38. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
39. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Li S; Liu J; Guo H; Gawade PL; Kim C; Bensink ME; Chandler D
Support Care Cancer; 2020 Jun; 28(6):2637-2649. PubMed ID: 31624920
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.
Volovat C; Gladkov OA; Bondarenko IM; Barash S; Buchner A; Bias P; Adar L; Avisar N
Clin Breast Cancer; 2014 Apr; 14(2):101-8. PubMed ID: 24485296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]